SCHEMBL1362345

SCHEMBL1362345

CCCOCCCNC(=O)c1cccc(Nc2nccc(-c3c(-c4cccc(NC(=O)Cc5ccccc5)c4)nc4sccn34)n2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 14/20 0.66
EGFR P00533 10/20 0.66
ERBB2 P04626 10/20 0.66
PTK2 Q05397 5/20 0.66
CDK19 Q9BWU1 1/20 0.66
KDR P35968 11/20 0.66
STK3 Q13188 9/20 0.66
MAP4K5 Q9Y4K4 9/20 0.66
RET P07949 8/20 0.66
CSF1R P07333 8/20 0.66
MAP4K2 Q12851 6/20 0.66
FLT1 P17948 6/20 0.66
LCK P06239 8/20 0.62
TAOK1 Q7L7X3 7/20 0.62
MAP4K4 O95819 6/20 0.62
AURKB Q96GD4 6/20 0.62
FYN P06241 5/20 0.62
FGFR1 P11362 5/20 0.62
PRKD3 O94806 4/20 0.62
MINK1 Q8N4C8 4/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1362361 0.94 IGF1R (0.69) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1364427 0.92 IGF1R (0.69) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1363301 0.90 IGF1R (0.69) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1361336 0.90 IGF1R (0.69) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1361168 0.89 IGF1R (0.78) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1362983 0.88 IGF1R (0.81) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1362248 0.87 IGF1R (0.65) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1361862 0.86 IGF1R (0.72) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1363609 0.86 IGF1R (0.69) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1361307 0.86 IGF1R (0.78) IGF1REGFRERBB2PTK2CDK19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 US claimed
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 US disclosed
EP-2222682-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2010-09-01 EP disclosed
US-20090253723-A1 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-10-08 US disclosed
WO-2009070516-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253723-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 IGF1R 1941/4885EGFR 591/4885ERBB2 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.